Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA review speeds up

This article was originally published in The Tan Sheet

Executive Summary

FDA is approving abbreviated new drug applications at a faster pace in fiscal 2004 than in FY 2003. From October 2003 through August 2004, the agency's Office of Generic Drugs approved 289 original ANDAs - five more than were cleared in all of FY 2003. The agency also tentatively approved 83 applications in the first 11 months of FY 2004, compared to 89 tentative approvals in all of FY 2003. FDA attributes the improvements to increased staff, better training and changes in procedures, which allow reviewers to verbally communicate application deficiencies to sponsors. FDA anticipates that FY 2004 also will show a surge in the total number of generic applications received, as well as a decline in the average review time for ANDAs...

You may also be interested in...

Bayer Execs On Digital Acceleration, Getting The Building Blocks Right

Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”

US FDA Credibility: Surprisingly Strong, Despite Everything

A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts